Cell Therapeutics CEO Should Resign: Opinion
SEATTLE (TheStreet) -- Dear Jim:
You want to sue me? Really?
During Friday afternoon's conference call, you said Cell Therapeutics (CTIC) was considering a lawsuit against my employer, TheStreet.com, and me because, "It is time we take action to stand up for retail shareholders across all such fronts, especially when misstatements are made with malicious intent or a reckless disregard for the truth."
![]() |
| Cell Therapeutics CEO Jim Bianco |
Jim Bianco, if you really want to protect the interests of your shareholders, retail or otherwise, you should resign from your post as CEO of Cell Therapeutics immediately.
Seriously, Jim. Resign now. Leave and take your entire management team with you. Instruct your board of directors to appoint a caretaker executive as interim CEO whose primary task will be to sell off whatever assets the company has left. Use the proceeds to pay off the debt on Cell Therapeutics' balance sheet. If there's any money remaining, return it to shareholders as a small token compensation for the years of losses they've endured under your incompetent and wasteful reign as Cell Therapeutics' chief executive. Listening to you suggest that you're safeguarding the financial interests of shareholders would be laughable if it weren't such a pathetic misrepresentation of the facts. Since 2005, Cell Therapeutics' shares have lost 99.9% of their value. I ran a screen for the worst performing biotech stocks over the past five years. Congratulations Jim, Cell Therapeutics is ranked No. 1. The only biotech firms that lost more value since 2005 than Cell Therapeutics are those that went belly up. While shareholders have been wiped out, you've become a very wealthy man. You could say Cell Therapeutics is your personal ATM. It's a great system (for you), shareholders make the deposits and you make the withdrawals. Since 2005, you've collected well more than $20 million in total compensation, which includes salary, bonuses, stock awards and perks like private jet travel, "personal protective services" for you and your family and health club membership dues. (You can't pay for your own gym membership?) In 2009, you earned $12 million in total compensation. The top five executives of your management team earned $32 million in total compensation. Cell Therapeutics reported an operating loss of more than $81 million. Meantime, under your direction, Cell Therapeutics' total share count has now ballooned to almost 700 million, if it's not past that already.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
